Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Intra-Cellular Surges On First Phase III Schizophrenia Data

This article was originally published in Scrip

Executive Summary

Intra-Cellular Therapies saw its share price climb 86.9% to close at a new peak of $48.79 on Sept. 16 after the company reported that ITI-007 showed a potentially differentiated safety profile relative to approved antipsychotic drugs in the first of two Phase III schizophrenia clinical trials.

Advertisement

Related Content

Surprise Failure for Intra-Cellular Therapies’ Schizophrenia Drug Sends Shares Tumbling

Topics

Advertisement
UsernamePublicRestriction

Register

SC029778

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel